NCT07147348View on ClinicalTrials.gov

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

BNT3212

Intravenous infusion

BIOLOGICAL

BNT327

Intravenous infusion

Trial Locations (2)

2031

NOT_YET_RECRUITING

Scientia Clinical Research Limited, Randwick

200120

RECRUITING

Shanghai East Hospital, Shanghai

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
collaborator

Biotheus (Hengqin) Co., Ltd.

UNKNOWN

collaborator

BioNTech (Shanghai) Pharmaceuticals Co., Ltd.

UNKNOWN

lead

BioNTech SE

INDUSTRY

NCT07147348 - A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter